Rifampicin (Rifadin) tab 300 mg: Supply issue

Supply issue Active

Sanofi is out of stock of Rifampicin tab 300 mg due to an equipment problem at the manufacturing facility.

15 March 2024 update

Resupply of the original Rifadin brand 300 mg capsules has been delayed until December 2024. Rifadin Sanofi will continue to be supplied until then.

Affected product

Because of an issue with equipment at the manufacturing facility, Sanofi is out of stock of rifampicin tab 300 mg.

  • Chemical: Rifampicin
  • Presentation: Cap 300 mg
  • Brand: Rifadin
  • Pharmacode: 251194 
  • Subsidy: $122.06
  • Measure / Qty: per 100

Alternate product listed

Sanofi has arranged alternative stock from the United Kingdom. Sanofi advise that Medsafe has granted a labelling exemption for this product.  

Medsafe product approval detail(external link)

  • Brand: Rifadin Sanofi 
  • Pharmacode: 2669838 
  • Subsidy: $122.06
  • Measure / Qty: per 100

Schedule listing for rifampicin(external link)

Rifadin Datasheet - Medsafe website [PDF](external link)

Resupply expected December 2024

Sanofi expects normal supply to resume in December 2024.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.  

Sign up to our email list for regular emails about supply issues and more(external link)